CADTH has received notice of a pending submission from Amgen for evolocumab (Repatha) for the treatment of patients with primary hyperlipidaemia, mixed dyslipidaemia and homozygous familial hypercholesterolaemia.  For information about the patient input process or for additional instructions, please see the patient input page of the CADTH website. Note that typically only patient groups may submit input; however, there is currently a pilot process for receiving patient input submissions from individual patients and caregivers.

For more details, go to: https://www.cadth.ca/cdr/patient-input/open-calls-for-patient-input/cdr-patient-input-submission?brand_name=Repatha&generic_name=Evolocumab&indicator=Primary%20hyperlipidemia%2C%20mixed%20dyslipidemia%2C%20homozygous%20familial%20hypercholesterolemia